Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06419621
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-14
Brief Title:
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally AdvancedMetastatic Triple-negative Breast Cancer
Sponsor:
Biotheus Inc
Organization:
Biotheus Inc
Study Overview
Official Title:
A Multicenter Randomized Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally AdvancedMetastatic Triple-negative Breast CancerTNBC
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multicenter randomized double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally advancedmetastatic triple-negative breast cancerTNBC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None